Y-mAbs Therapeutics Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street mixed as oil prices surge, investors await earnings, economic data
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Y-mAbs Therapeutics (YMAB) IPO Opens 67% Higher
September 21, 2018 11:03 AM EDTToday's IPO for Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) opened for tradign at $26.50 after pricing 6,000,000 shares of common stock at a public offering price of $16.00 per share.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional... More



